Linked Life Data

10918197

Source:http://linkedlifedata.com/resource/pubmed/id/10918197

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-8-18
pubmed:abstractText
We have identified an H-2K(d)-binding peptide, HER2p780 (PYVSRLLGI), derived from murine HER2/neu (HER2), that can induce HER2-specific murine cytotoxic T lymphocytes (CTL). Weekly vaccination of BALB/c mice by syngeneic dendritic cells pulsed with HER2p780 peptide, entirely common to murine and human HER2, suppressed growth of pretransplanted HER2-expressing syngeneic tumors. A HER2-expressing human cancer cell line SKOV3 transfected with murine H-2K(d) cDNA could also be lysed by HER2p780-specific murine CTLs, indicating that human HER2-expressing cancer cells can process and present the cognate peptide in the context of H-2K(d). Since H-2K(d) and HLA-A2402 molecules have similar anchor motifs, the possibility of inducing HER2-specific CTL activity with HER2p780 in HLA-A2402 individuals was examined. CD8(+) CTL clones specific for HER2-expressing cancer cell lines were established from peripheral blood lymphocytes with HLA-A2402 by repeatedly sensitizing with peptide-pulsed autologous dendritic cells as well as peripheral blood mononuclear cells. Detailed analysis of their specificity revealed that the cytotoxicity of CTL clones is specific for the cognate peptide with HLA-A2402 restriction. The results suggest that HER2p780 is a unique peptide that may function as a tumor rejection antigen peptide in HLA-A2402 individuals, as it was directly proven here to function in a murine tumor system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2000 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
87
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
553-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:10918197-Animals, pubmed-meshheading:10918197-Antibodies, Monoclonal, pubmed-meshheading:10918197-Antigen Presentation, pubmed-meshheading:10918197-Antigens, CD3, pubmed-meshheading:10918197-Antigens, CD8, pubmed-meshheading:10918197-Antigens, Neoplasm, pubmed-meshheading:10918197-Cancer Vaccines, pubmed-meshheading:10918197-Clone Cells, pubmed-meshheading:10918197-Dendritic Cells, pubmed-meshheading:10918197-Epitopes, T-Lymphocyte, pubmed-meshheading:10918197-HLA-A Antigens, pubmed-meshheading:10918197-HLA-A24 Antigen, pubmed-meshheading:10918197-Humans, pubmed-meshheading:10918197-Lymphocyte Activation, pubmed-meshheading:10918197-Mice, pubmed-meshheading:10918197-Neoplasm Transplantation, pubmed-meshheading:10918197-Peptide Fragments, pubmed-meshheading:10918197-Receptor, erbB-2, pubmed-meshheading:10918197-T-Lymphocytes, Cytotoxic, pubmed-meshheading:10918197-Tumor Cells, Cultured
pubmed:year
2000
pubmed:articleTitle
A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
pubmed:affiliation
Second Department of Internal Medicine, Mie University School of Medicine, Mie, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't